what is micro dose tirzepatide Microdosing chart: complete week-by-week dosing guide Microdose Tirzepatide: Maintenance GLP-1 |

If you experience any suspected side effects, report them to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk)

Richard DiMarchi, one of the pioneers of GLP-1 drugs, argues that the degree which they have helped to manage excess body weight compares with the historic breakthroughs in the management of excess blood pressure, excess lipids and excess glucose

Park Cheol-young, Chairman of the Korean Society for the Study of Obesity (Endocrinology Department, Kangbuk Samsung Hospital), emphasized, Obesity is a chronic disease affecting approximately 17 million adults in South Korea, increasing the risk of over 200 complications such as type 2 diabetes and cardiovascular diseases

These increases in heart rate are more pronounced in the longer-acting GLP-1 agonists such as semaglutide and tirzepatide. Aside from heart conditions, you should also avoid semaglutide if you have any of the following conditions or situations: Type 1 diabetes mellitus A history of medullary thyroid carcinoma (MTC) Chronic stomach problems Eye disease or vision problems Medical history of pancreatitis Hypersensitivity to the drugs or its active ingredients Severe gastrointestinal diseases Kidney disease Are pregnant or breastfeeding If you have a pre-existing heart condition, please notify your healthcare provider so that they can decide whether semaglutide is a safe medication for you

But still this medicine can impact patients digestion and can cause patients to be less hungry

But it can also help address daily burdens such as migraine, depression and menopause-related challenges